In T2DM, there is an “incretin defect,” manifested through the reduction in incretin bioavailability, which in part is due to their rapid inactivation by dipeptidyl peptidase-4 (DPP-4) [8]. This evidence concerns the gene GCG and type 2 diabetes mellitus.